Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01257932

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
University of California, Irvine · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients.

Detailed description

The investigators are testing the effectiveness of an experimental imaging technology known as Diffuse Optical Spectroscopy Imaging in predicting the success of chemotherapy treatment (shrinkage of tumor). Diffuse optical spectroscopic imaging measurements are made with a laser breast scanner. This bedside-capable system combines frequency-domain photon migration with steady-state tissue spectroscopy to measure complete(broadband) near-infrared absorption and reduced scattering spectra of breast tissue in vivo. Diffuse Optical Spectroscopy Imaging measurements are made by placing the hand-held probe on the tissue surface and moving the probe to discrete locations along a grid pattern at 1.0 cm intervals. The portable high-bandwidth Frequency-Domain Photon Migration instrument employs intensity-modulated diode lasers and conventional steady-state lamps as sources and an avalanche photodiode as the detector. The time required to perform an Frequency-Domain Photon Migration measurement depends on the desired precision and number of sweeps.

Conditions

Interventions

TypeNameDescription
DEVICEDiffuse Optical Spectroscopy ImagingDiffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy

Timeline

Start date
2010-12-01
Primary completion
2013-10-01
Completion
2013-10-01
First posted
2010-12-10
Last updated
2022-11-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01257932. Inclusion in this directory is not an endorsement.